SAB Biotherapeutics
SABS
87 hedge funds and large institutions have $267M invested in SAB Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 21 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
52% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 21
14% more funds holding
Funds holding: 76 → 87 (+11)
1% more capital invested
Capital invested by funds: $265M → $267M (+$1.74M)
18% less call options, than puts
Call options by funds: $760K | Put options by funds: $923K
46.35% less ownership
Funds ownership: 135.8% → 89.45% (-46%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.2M |
| 2 |
BlackRock
New York
|
+$10.3M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.63M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$3.53M |
| 5 |
SFCM
Seven Fleet Capital Management
Mountain View,
California
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$15.3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$6.22M |
| 3 |
CC
Commodore Capital
New York
|
-$5.7M |
| 4 |
JFG
Jefferies Financial Group
New York
|
-$3.46M |
| 5 |
Blackstone Inc
New York
|
-$3.29M |
SABS Hedge Fund Activity: Q2 2026 in Review
87 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2026, worth a combined $267M — up 0.66% from $265M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SABS positions and 21 closed out — a net gain of 11 holders — while 25 added to existing stakes and 16 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $11.2M. The largest seller was Vivo Capital, cutting an estimated $15.3M.
- 87 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2026, up from 76 in Q1 2026.
- Funds reported $267M of SAB Biotherapeutics stock for Q2 2026, up 0.66% quarter-over-quarter.
- 32 funds opened new SAB Biotherapeutics positions in Q2 2026 and 21 closed out, a net change of +11 holders.
- The largest SAB Biotherapeutics buyer in Q2 2026 was Adage Capital Partners, an estimated $11.2M added.
- The largest SAB Biotherapeutics seller in Q2 2026 was Vivo Capital, an estimated $15.3M sold.
Based on aggregated 13F filings for Q2 2026.